Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- Altru Cancer Center — Grand Forks, North Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in North Dakota: - Sanford Broadway Medical Center — Fargo, North Dakota
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in North Dakota: - Research Site — Grand Forks, North Dakota
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in North Dakota: - Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063) — Fargo, North Dakota
- Altru Health System ( Site 0040) — Grand Forks, North Dakota
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if p…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07513376
Sites in North Dakota: - Altru Health System ( Site 3254) — Grand Forks, North Dakota
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in North Dakota: - Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immun…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06731907
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gen…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in North Dakota: - Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in North Dakota: - Massive Bio SYNERGY-AI site — Fargo, North Dakota